CANY
NRIX icon

Caxton Associates (New York)’s Nurix Therapeutics NRIX Stock Holding History

Caxton Associates (New York)’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,767
Closed -$642K – 610
2024
Q2 		$642K Buy
30,767
+15,453
+101% +$241K 0.02% 306
2024
Q1 		$225K Buy
+15,314
New +$165K 0.01% 418

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Caxton Associates (New York)'s NRIX Position: Q3 2024 in Review

Caxton Associates (New York) sold out of Nurix Therapeutics (NRIX) in Q3 2024, closing a stake of 30,767 shares — an estimated $642K sold.

Caxton Associates (New York) first reported a position in NRIX in Q1 2024 and held it in 2 quarters. The position peaked at $642K in Q2 2024. 172 funds tracked by Wall St. Rank hold NRIX as of Q3 2024.

  • Caxton Associates (New York) reported no remaining Nurix Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 30,767 Nurix Therapeutics shares in Q3 2024, an estimated $642K.
  • Caxton Associates (New York) first reported a position in Nurix Therapeutics in Q1 2024 and held it in 2 quarters.
  • Caxton Associates (New York)'s Nurix Therapeutics position peaked at $642K in Q2 2024.
  • 172 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2024.

Based on Caxton Associates (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.